OmniTier specializes in end-to-end genomic analysis solutions that are designed to provide fast, accurate, and cost-effective analysis of genomic data. Their flagship product, the CompStor® platform, is a standalone appliance that supports both secondary and tertiary analysis of genomic data, making it suitable for a variety of applications, including clinical diagnostics and research. The platform is capable of handling large volumes of data, from whole exomes to whole genomes, and is designed to scale according to the needs of the user. It integrates advanced AI-based variant interpretation capabilities, which enhance diagnostic accuracy by identifying true causal variants more effectively. This is particularly beneficial in the context of rare disease diagnostics, where precision is critical.

The CompStor® platform is built to operate in on-premise data centers, ensuring greater control over patient data and enhanced security compared to cloud-based solutions. It supports multiple sequencing technologies, including those from Illumina, MGI Tech, Oxford Nanopore Technology, and PacBio. The system features two proprietary variant callers, including OmniTier’s Novos variant caller, which is designed to deliver high-quality variant calls while minimizing false positives. With automated workflows and user-friendly interfaces, OmniTier's solutions empower researchers, clinicians, and bioinformaticians to implement their own methodologies efficiently, thereby facilitating a more personalized approach to genomic healthcare.

United States

OmniTier Inc. develops easy to use, end-to-end, genomic analysis on-premise and cloud based systems that achieve greater accuracy and faster run-times than competing offerings. 

OmniTier

Company Details